Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy

Endocrine Journal

Volumn 56, Issue 6, 2009, Pages 739-746

  Kaku, Kohei ^a   Tanaka, Shun Ichi ^b   Origasa, Hideki ^c   Kikuchi, Masatoshi ^d   Akanuma, Yasuo ^d  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Kanazawa Medical Clinic   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d INSTITUTE FOR ADULT DISEASES   (Japan)

Author keywords

Combination therapy; Mitiglinide; Pioglitazone; Type 2 diabetes

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MITIGLINIDE; PIOGLITAZONE;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; INSOMNIA; INSULIN RELEASE; INSULIN RESISTANCE; JAPANESE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PANCREAS CARCINOMA; PERIPHERAL EDEMA; SIDE EFFECT; THIRST; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; ISOINDOLES; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TIME FACTORS; WEIGHT GAIN;

EID: 70349973565     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K09E-023     Document Type: Article

References (18)

1. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in pathogenesis of type 2 diabetes mellitus. J Clin Invest 104: 784-794. (Pubitemid 29536364)
2. DECODE Study Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617-621.
3. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22: 920-924.
4. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25: 10-16. (Pubitemid 38055587)
5. Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S, Sato F (1994) Novel rapid- and short-acting hypoglycemic agent, a calcium (2s)-2-benzyl-3- (cis-hexahydro-2- isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther 269: 489-495. (Pubitemid 24157312)
6. + channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. Eur J Pharmacol 269: 293-298.
7. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ (1994) Ionophoretic activity of meglitinide analogues. Diabetes Res 27: 61-71.
8. + channels and insulin secretion: comparison with the sulufonylureas and nateglinide. Eur J Pharmacol 431: 119-125.
9. Reimann F, Proks P, Ashcroft FM (2001) Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol 132: 1542-1548. (Pubitemid 32281043)
10. Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y (2007) Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract 76: 229-235. (Pubitemid 46400132)
11. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In Macrovascular Events): a randomized controlled trial. Lancet 366: 1279-1289. (Pubitemid 41416583)
12. American Diabetes Association (2007) Standards of medical care in diabetes - 2007. Diabetes Care 30 Suppl 1: S4-S41. (Pubitemid 46048398)
13. Risso A, Mercuri L, Quagliaro G, Damante G, Ceriello A (2001) Intermittent high glucose enhances apoptosis in human umbilical vein endothelical cells in culture. Am J Physiol Endocrinol Metab 281: E924-E930. (Pubitemid 33123798)
14. Assaloni R, Da Ros R, Quagliaro L, Piconi L, Maier A, Zuodar G, Motz E, Ceriello A (2005) Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 48: 1919-1924. (Pubitemid 41317849)
15. Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 26: 881-885.
16. Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE (2003) Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 26: 1685-1690. (Pubitemid 36929104)
17. Jovanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, Hale PM (2004) Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 63: 127-134. (Pubitemid 38096358)
18. Rosenstock J, Gatlin MR, Shen S, Foley JE (2002) Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 25: 1529-1533. (Pubitemid 41071106)